The FDA recently approved Vyleesi (bremelanotide) as a treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It’s administered as an injection, typically 45 minutes before anticipated sexual activity.
How does Vyleesi work?
Vyleesi works differently than other medications. It acts on melanocortin receptors in the brain, affecting neurotransmitters involved in sexual desire. This leads to increased sexual arousal and desire.
Important Considerations:
Vyleesi isn’t for everyone. It’s only approved for premenopausal women with HSDD and carries potential side effects like nausea, vomiting, flushing, and headache. Patients should discuss these risks and benefits with their doctor to determine suitability. Additionally, there may be interactions with other medications, so complete disclosure of all medications is crucial.
